Magnesium taurate

Magnesium taurate, also known as magnesium ditaurate,[1] is the magnesium salt of taurine, and a mineral supplement.[2]

Its molecular weight is 272.58288 g/mol.[3] As such, it contains 8.9% elemental magnesium by mass. Accordingly, 100 mg of magnesium is contained in 1121 mg of magnesium taurate.

Uses

Magnesium taurate has been suggested with applicability to vascular protection,[2] myocardial infarction,[2] pre-eclampsia,[2][4] eclampsia,[4] perinatal asphyxia,[4] and migraine.[5] It has been studied in rats for delaying the onset and progression of cataract.[6]

Safety

Due to the expected dissociation of magnesium taurate in the body before absorption, safety data on magnesium and taurine can be used to evaluate the safety of magnesium taurate.[1]

Taurine has an observed safe level of supplemental intake in normal healthy adults at up to 3 g/day.[7] Using the same level as an approximation for taurate yields a limit of 3.3 g/day for magnesium taurate, or alternatively 300 mg/day for elemental magnesium as taurate.

See also

References

  1. 1 2 "Scientific Opinion of the Panel on Food Additives and Nutrient Sources added to Food on iron (II) taurate, magnesium taurate and magnesium acetyl taurate as sources for iron or magnesium to be added as a nutritional substance in food supplements following a request from the European Commission" (PDF). 2009.
    • Synonyms for magnesium taurate are: magnesium taurinate, magnesium 2-aminoethane sulfonic acid and magnesium ditaurate.
    • Due to the expected dissociation of magnesium taurate in the body before absorption, data on magnesium and taurate (or taurine) can be used to evaluate the safety of magnesium taurate.
  2. 1 2 3 4 McCarty MF (1996). "Complementary vascular-protective actions of magnesium and taurine: a rationale for magnesium taurate". Medical Hypotheses 46 (2): 89–100. PMID 8692051. Retrieved 2016-01-31. The complex magnesium taurate may thus have considerable potential as a vascular-protective nutritional supplement, and might also be administered parenterally, as an alternative to magnesium sulfate, in the treatment of acute myocardial infarction as well as of pre-eclampsia.
  3. ↑ "UNII-RCM1N3D968".
  4. 1 2 3 McCarty MF (1996). "Magnesium taurate for the prevention and treatment of pre-eclampsia/eclampsia". Medical Hypotheses 47 (4): 269–72. PMID 8910874. Retrieved 2016-01-31. parenteral magnesium taurate can reasonably be proposed as a superior alternative to magnesium sulfate in the treatment of pre-eclampsia; administered orally as a component of prenatal supplementation, magnesium taurate might well have both preventive and therapeutic value in this syndrome. In the light of the hypoxia-protective actions of both magnesium and taurine, such supplementation might also protect fetuses experiencing temporary perinatal asphyxia, lessening the risk of cerebral palsy.
  5. ↑ McCarty MF (1996). "Magnesium taurate and fish oil for prevention of migraine". Medical Hypotheses 47 (6): 461–6. PMID 8961243. it is reasonable to speculate that supplemental magnesium taurate will have preventive value in the treatment of migraine.
  6. ↑ Agarwal R, Iezhitsa I, Awaludin NA, Ahmad Fisol NF, Bakar NS, Agarwal P, Abdul Rahman TH, Spasov A, Ozerov A, Mohamed Ahmed Salama MS, Mohd Ismail N (2013). "Effects of magnesium taurate on the onset and progression of galactose-induced experimental cataract: in vivo and in vitro evaluation". Experimental Eye Research 110: 35–43. doi:10.1016/j.exer.2013.02.011. PMID 23428743. Retrieved 2016-01-31. Both in vivo and in vitro studies demonstrated that treatment with magnesium taurate delays the onset and progression of cataract in galactose fed rats by restoring the lens Ca(2+)/Mg(2+) ratio and lens redox status.
  7. ↑ Shao A, Hathcock JN (2008). "Risk assessment for the amino acids taurine, L-glutamine and L-arginine". Regulatory Toxicology and Pharmacology : RTP 50 (3): 376–99. doi:10.1016/j.yrtph.2008.01.004. PMID 18325648. Retrieved 2016-02-02. the newer method described as the Observed Safe Level (OSL) or Highest Observed Intake (HOI) was utilized. The OSL risk assessments indicate that based on the available published human clinical trial data, the evidence for the absence of adverse effects is strong for Tau at supplemental intakes up to 3 g/d, Gln at intakes up to 14 g/d and Arg at intakes up to 20 g/d, and these levels are identified as the respective OSLs for normal healthy adults.
This article is issued from Wikipedia - version of the Sunday, March 06, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.